Amgen reported $38.1B of revenue over the trailing twelve months, +9.1% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $38.1B (to Q2 2026). Net Income: $8.74B, trailing twelve months to Q2 2026. Free Cash Flow: $10.2B, trailing twelve months to Q2 2026. Op Margin: 30%, trailing twelve months to Q2 2026.

AMGNAmgen

HealthcareUSD

$440.34

$265.4052 weeks$443.80

AMGN as reported

Amgen reported $38.1B of revenue over the trailing twelve months, +9.1% on the year before. 11 reported series are charted on this page, each one as filed.

$38.1B

Revenue, trailing twelve months · to Q2 2026 · +9.1% against the twelve months before

Net Income: $8.74B
Net Income · +32% year on year · trailing twelve months to Q2 2026
Free Cash Flow: $10.2B
Free Cash Flow · −4.1% year on year · trailing twelve months to Q2 2026
Op Margin: 30%
Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for AMGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$38.1B	+9.1%	Q2 2026
Net Income	$8.74B	+32%	Q2 2026
EPS	$16.10	+32%	Q2 2026
Gross Margin	69%	n/a	Q2 2026
Op Margin	30%	n/a	Q2 2026
Net Margin	23%	n/a	Q2 2026
ROE	80%	n/a	Q2 2026
ROA	8.5%	n/a	Q2 2026
ROIC	14%	n/a	Q2 2026
Free Cash Flow	$10.2B	−4.1%	Q2 2026
P/E	27.4	n/a	today